12,372 trials
Anesthesia, Local
Primary: The Percentage of Patients Who Experienced Ocular Anesthesia Following Treatment of AG-920 Compared to Placebo at 5 Minutes — 50; 11; 10; 49 Participants
Hepatorenal Syndrome
Primary: Improvement of Renal Function (SCr) From Day 1 Thru End of Treatment, Repeated Measure Analysis. SCr Will be Collected Daily, From Day 1 Thru End of Treatment. Baseline…
Herpes Simplex
Primary: Percentage of Participants With Healing by Day 8 — 66.4; 69.5 Percentage of Participants — p=0.5086
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
Primary: Double Blind Phase: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 in Seronegative Participants With Onset at…
Atopic Dermatitis Eczema
Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 32.0; 15.2 percentage of participants — p=<0.0001
Anesthesia, Local
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 40; 13 Participants
Generalized Pustular Psoriasis
Primary: Occurrence of Treatment Emergent Adverse Events (AEs) — 18; 12 Participants
Pleural Effusion · Single-ventricle
Primary: Chest Tube Drainage — 686.83; 535.50 ml/kg
Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.7; -1.6 Percentage of glycosylated haemoglobin — p=<.0001
Rheumatoid Arthritis
Primary: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 — -3.77; -3.67 units on a scale
Osteoarthritis of the Knee
Primary: Change From Baseline in WOMAC Pain at Week 12 for TLC599 12 mg Versus Placebo — -0.968; -0.798 score on a scale — p=0.0372
Prurigo Nodularis
Primary: Time From Baseline to Relapse Meeting At Least 1 of the Defined Criteria — NA; 112.50 Days
Atrial Fibrillation · Cardioversion · Cerebrovascular Stroke
Primary: Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli — 9; 11 Participants
Fabry Disease
Primary: Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) — 2 Participants
Adenocarcinoma of the Prostate
Primary: Efficacy of Sipuleucel-T Measured as the Percentage of Subjects Without Histological Reclassification (Gleason Group Upgrade). — 108; 48 Participants — p=0.4586